Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) said for the three months ended 30 September 2021, net profit attributable to shareholders of the listed company was RMB1.08 billion, a year-on-year increase of 41.62%. Basic earnings per share were RMB0.42.
Operating revenue was RMB10.10 billion, a year-on-year increase of 25.03%.
全新節目《說說心理話》青少年不可以戀愛!?真實個案講述驚心動魄經歷► 即睇